# One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

> **NCT01139021** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 508 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** rMenB+OMV NZ

## Key facts

- **NCT ID:** NCT01139021
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-11
- **Final completion:** 2011-09
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2015-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01139021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01139021, "One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01139021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*